EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2)

Yoshiya Tanaka iD, Tsutomu Takeuchi, Yoshiaki Morita, Yuichiro Kaneko, Wataru Terada

Modern Rheumatology · 2024

DOI: 10.1093/mr/road110 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yoshiya Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Remission Induction, Niacinamide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This post hoc analysis of the RAJ2 study assessed long-term safety and effectiveness of peficitinib 100 mg/day for treatment of rheumatoid arthritis.

Methods

Eligible patients previously completed two Phase 3 (RAJ3 and RAJ4) studies of peficitinib in Asia. All patients received peficitinib 100 mg/day at RAJ2 Week (W)0; dose change to 50 mg/day or 150 mg/day was permitted. Safety endpoints included treatment-emergent adverse events and laboratory test results. Effectiveness endpoints included peficitinib exposure pattern, achievement of Clinical Disease Activity Index (CDAI) remission by peficitinib exposure pattern at W0 and W48, and association of demographics/characteristics with CDAI remission at W0 and W48.

Results

Overall, no new safety findings were reported at W48, and renal function was unaffected. Of patients included in effectiveness analyses at W48, 70.9% (451/636) had maintained peficitinib 100 mg/day since W0. Of patients who achieved CDAI remission at W0 and maintained peficitinib 100 mg/day to W48, 50.3% (79/157) maintained CDAI remission to W48. Low disease activity and a lower number of prior disease-modifying antirheumatic drugs were significantly associated with CDAI remission at W48.

Conclusions

Long-term peficitinib treatment at a dose of 100 mg/day was generally well tolerated and, following induction therapy, maintained effectiveness through to W48.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsRemission InductionNiacinamideHumansMaleFemaleMiddle AgedTreatment OutcomeAdultRepublic of KoreaTaiwanAgedJapanAdamantane

Stichwörter der Autor:innen

Peficitinibremissionrheumatoid arthritissafetytargeted synthetic DMARDs

Substanzen

Antirheumatic AgentspeficitinibNiacinamideAdamantane

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Saitama Medical University, Saitama, Japan.
  • Medical Affairs Japan, Astellas Pharma Inc., Tokyo, Japan.
  • Statistical & RWD Science Group, Data Science, Astellas Pharma Global Development Inc., Northbrook, IL, USA.
  • Statistical & RWD Science Group, Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.

ORCID-Profile: Yoshiya Tanaka

Zitieren

APA

Tanaka, Y., Takeuchi, T., Morita, Y., Kaneko, Y., & Terada, W. (2024). Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2). Modern Rheumatology. https://doi.org/10.1093/mr/road110

Vancouver

Tanaka Y, Takeuchi T, Morita Y, Kaneko Y, Terada W. Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2). Modern Rheumatology. 2024. doi:10.1093/mr/road110

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Yoshiya and Takeuchi, Tsutomu and Morita, Yoshiaki and Kaneko, Yuichiro and Terada, Wataru},
  title = {Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2)},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road110}
}
Kostenlos starten →